Displaying drugs 15076 - 15100 of 15190 in total
(R)-acetoin
A product of fermentation. It is a component of the butanediol cycle in microorganisms. In mammals it is oxidized to carbon dioxide.
Experimental
NRP409
NRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.
Investigational
Dapansutrile
Dapansutrile is under investigation in clinical trial NCT01768975 (Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee).
Investigational
Tin protoporphyrin IX
Investigational
Cambinol
Cambinol is a beta-naphtol derivative that inhibits NAD-dependant deacetylases to reduce cell survival under stress. This activity is currently being investigated for its use as a cancer treatment.
Experimental
2,3-Dimethyl-1,4-naphthoquinone
Experimental
1-Amino-1-Carbonyl Pentane
Experimental
Acetophenone
Experimental
Atl146e
ATL146e is an anti-inflammatory compounds which is an agonist of A2A adenosine receptors.
Investigational
PH94B
PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder). It is a member of a new family of pharmaceutical compounds called vomeropherins.
Investigational
Nitrosoethane
Experimental
REN-850
REN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.
Investigational
Napabucasin
Napabucasin has been investigated for the treatment of Colorectal Carcinoma.
Investigational
AP5346
AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer. It is being pursued by Access Pharmaceuticals, Inc.
Investigational
Terevalefim
Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).
Investigational
1,1,1-TRIFLUORO-3-(OCTYLTHIO)ACETONE
Experimental
9-Deazahypoxanthine
Experimental
Pridopidine
Pridopidine has been used in trials studying the treatment of Huntington's Disease.
Investigational
Oxomemazine
Experimental
ALGRX 1207
ALGRX 1207 is a topical local anesthetic that acts by binding to the fast sodium channel. ALGRX 1207 entered clinical trials for cutaneous neuropathic pain, such as chemotherapy-induced neuropathy, in 2006. It was being developed by Anesiva, but trials have halted.
Investigational
2-Methyl-3-(2-Aminothiazolo)Propanal
Experimental
Displaying drugs 15076 - 15100 of 15190 in total